|1.||Ohkawa, Kiyoshi: 2 articles (05/2015 - 02/2004)|
|2.||Asakura, Tadashi: 2 articles (05/2015 - 02/2004)|
|3.||Kim, Kyung Bo: 2 articles (05/2013 - 09/2012)|
|4.||Prehn, J H M: 2 articles (10/2011 - 03/2007)|
|5.||Picken, Maria M: 2 articles (10/2010 - 12/2009)|
|6.||Majetschak, Matthias: 2 articles (10/2010 - 12/2009)|
|7.||Baker, Todd A: 2 articles (10/2010 - 12/2009)|
|8.||Gamelli, Richard L: 2 articles (10/2010 - 12/2009)|
|9.||Romero, Jacqueline: 2 articles (10/2010 - 12/2009)|
|10.||Geng, Qing: 2 articles (10/2010 - 12/2009)|
08/05/2004 - "The proteasome inhibitors, epoxomicin, lactacystin and carbobenzoxy-leucyl-leucyl-leucinal, stimulate the release of arachidonic acid from rat glial, human colon carcinoma, human breast carcinoma and the rat liver cells. "
05/15/2009 - "We quantitatively compared the efficacy of various proteasome inhibitors (MG132, lactacystin and epoxomicin) and IKK inhibitors (BAY 11-7082 and PS1145) to block NFkappaB activity induced by TNFalpha or TPA and to sensitize LNCaP prostate carcinoma cells to apoptosis. "
01/01/2014 - "Another goal was to assess the effects of administration of a specific proteasome inhibitor (epoxomicin, 0.5 mg/kg) on UPP response to sepsis. "
06/01/2009 - "The objective of this study was to determine if administration of proteasomal inhibitors (MG132, epoxomicin, bortezomib) can prevent sepsis-induced diaphragm weakness. "
05/01/2013 - "After its initial discovery by Bristol-Myers Squibb as a microbial anti-tumor natural product, epoxomicin was deemed unfit for development due to its peptide structure and potentially labile epoxyketone pharmacophore. "
01/20/2010 - "Thus, epoxomicin has been proposed as a potential anti-cancer drug. "
08/02/1999 - "Epoxomicin (1), a peptide alpha',beta'-epoxyketone isolated from the actinomycete strain No.Q996-17, possesses potent in vivo anti-tumor and anti-inflammatory activities. "
01/01/2014 - "The combination of APC and MG132, PI-1 or epoxomicin potently inhibited cancer cell growth, disrupted the cell cycle, induced apoptosis, decreased NF-κB activity and increased ROS production. "
12/01/2012 - "SCP and PIs: MG132, PI-1, or epoxomicin interact synergistically to potently inhibit cancer cell growth, alter cell cycle, induce apoptosis, reduce NFκB activity, and increase ROS generation. "
02/02/2012 - "Different functional proteomic approaches have been employed to tackle UPS impairment impact on human NeuroBlastoma (NB) cell lines responsive to proteasome inhibition by Epoxomicin. "
03/15/2007 - "To identify cell death pathways activated in response to inhibition of the proteasome system in cancer cells, we treated human SH-SY5Y neuroblastoma cells with the selective proteasome inhibitor (PI) epoxomicin (Epoxo). "
01/01/2013 - "We have shown previously, with cultured SH-SY5Y neuroblastoma cells, that proteasome inhibition by the drug epoxomicin results in accumulation of ubiquitinated proteins. "
05/01/2005 - "Firstly, SH-SY5Y human neuroblastoma cells were treated with different proteasome inhibitors, MG132, lactacystin, and epoxomicin. "
03/01/2011 - "We have shown that epoxomicin, a proteasome inhibitor, increases the levels of proteins involved in neurodegenerative disorders such as α-synuclein and hyper phosphorylated tau in NB69 human neuroblastoma cells and that such increase correlates with an enhanced rate of cell death. "
|2.||Proteasome Endopeptidase Complex (Proteasome)
|4.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|7.||3- (4- methylphenylsulfonyl)- 2- propenenitrile
|1.||Induced Heart Arrest (Cardioplegia)